secwatch.observer — SEC 8-K summary
======================================

Issuer:     WEST PHARMACEUTICAL SERVICES INC (WST)
CIK:        0000105770
Form:       8-K
Filed at:   2022-04-28T23:59:59+00:00
Accession:  0000105770-22-000014
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

West Pharma Q1 net sales $720M (+7.4%), adj. EPS $2.30; raises FY2022 adj. EPS guidance
--------------------------------------------------------------------------------

- Net sales $720.0M (+7.4% YoY); organic sales growth 11.0%.
- Reported diluted EPS $2.29 (+15.1%), adjusted diluted EPS $2.30 (+12.2%).
- Raises FY2022 adjusted EPS guidance to $9.30-$9.45 from $9.20-$9.35; reaffirms net sales $3.05B-$3.075B.
- Q3 dividend $0.18/share, payable Aug 3, record Jul 20; repurchased 390k shares for $147.1M.
- Proprietary Products segment sales $601.3M (+10.6%); HVP organic growth double-digit.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/105770/000010577022000014/0000105770-22-000014-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/105770/000010577022000014/wst-20220428.htm
  HTML page:      https://secwatch.observer/filing/0000105770-22-000014

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer